NCT06595706

Evaluating the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 in Healthy Adult Participants

A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Huge Biopharma Australia Pty Ltd · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

This study aims to determine the safety and pharmacokinetics of multiple ascending doses of Lucid-21-302 in healthy adult participants.

Conditions

• Heathy Participants

Interventions

Type	Name	Description
DRUG	Lucid-21-302	Capsule containing a small molecule inhibitor of hypercitrullination
DRUG	Placebo	Capsule containing only Silicified Microcrystalline Cellulose

Timeline

• Start date: 2024-09-28
• Primary completion: 2025-01-24
• Completion: 2025-01-24
• First posted: 2024-09-19
• Last updated: 2025-03-05

Locations

1 site across 1 country: Australia